2.5 mg semaglutide equivalent to tirzepatide vs dosage chart: complete comparison guide Tirzepatide vs Semaglutide 2026: 22%

Some patients use GLP-1 medications indefinitely as a chronic disease management tool

Genetic Variation in GLP-1 Receptor Sensitivity and Treatment Response Not all individuals respond identically to GLP-1 therapies

By script volume, GLP-1s have reached 2025M Americans

4 webinar, New Weight Loss Drugs Raise Issues of Coverage, Cost, Access and Equity, for which the recording is posted here.

The trial demonstrated a 20% reduction in the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (hazard ratio 0.80, 95% CI 0.72-0.90).[1] The trial also demonstrated improvements in multiple cardiovascular biomarkers independent of weight loss

However, some users diagnosed with Ozempic-induced gastroparesis report that the side effects persisted long after the drug is discontinued